The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 2, 2008, Pages 234-242

  Gaedigk, A ^a   Simon, S D ^a   Pearce, R E ^a   Bradford, L D ^b   Kennedy, M J ^c   Leeder, J S ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

^c University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DRUG METABOLITE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ETHNIC DIFFERENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; PHENOTYPE; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROTEIN FUNCTION; QUALITATIVE ANALYSIS; RACE DIFFERENCE; RNA TRANSLATION; SCORING SYSTEM;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; CLUSTER ANALYSIS; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENOTYPE; HUMANS; INFANT; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, GENETIC; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; REPRODUCIBILITY OF RESULTS; SUBSTRATE SPECIFICITY; UNITED STATES;

EID: 38349132802     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100406     Document Type: Article

References (32)

1. Gaedigk, A., Bradford, L.D., Marcucci, K.A. & Leeder, J.S. Unique CYP2D6 activity distribution and genotype-phenotype discordance in African Americans. Clin. Pharmacol. Ther. 72, 76-89 (2002).
2. Griese, U.E. et al. Assessment of the predictive power of genotypes for the in vivo catalytic function of CYP2D6 in a Caucasian population. Pharmacogenetics 8, 15-26 (1998).
3. Luo, H.-R., Gaedigk, A., Aloumanis, V. & Wan, Y.-J.Y. Identification of CYP2D6 impaired functional alleles in Mexican Americans. Eur. J. Clin. Pharmacol. 61, 797-802 (2005).
4. Tateishi, T., Chida, M., Ariyoshi, N., Mizorogi, Y., Kamataki, T. & Kobayashi, S. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin. Pharmacol. Ther. 65, 570-575 (1999).
5. Wennerholm, A. et al. The African-specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity. Clin. Pharmacol. Ther. 71, 77-88 (2002).
6. Oscarson, M., Hidestrand, M., Johansson, I. & Ingelman-Sundberg, M. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol. Pharmacol. 32, 1034-1040 (1997).
7. Cai, W.-M. et al. CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing. Pharmacogenomics J. 6, 343-350 (2006).
8. Bogni, A. et al. Substrate-specific metabolism by polymorphic cytochrome P450 2D6 alleles. Toxicol. In Vitro 19, 621-629 (2005).
9. Steimer, W. et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin. Chem. 50, 1623-1633 (2004).
10. Blake, M.J. et al. Ontogeny of drug metabolism by cytochrome P450 enzymes in the first year of life. Clin. Pharmacol. Ther. 81, 510-516 (2007).
11. Findling, R.L. et al. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology 31, 1274-1285 (2006).
12. Zineh, I. et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin. Pharmacol. Ther. 76, 536-544 (2005).
13. Gaedigk, A., Ndjountché, L., Leeder, J.S. & Bradford, L.D. Limited association of the 2988G > A single nucleotide polymorphism with CYP2D6*41 in black subjects. Clin. Pharmacol. Ther. 77, 228-230 (2005).
14. Zanger, U.M. et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11, 573-585 (2001).
15. Gaedigk, A. et al. Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J. 5, 173-182 (2005).
16. Corchero, J. et al. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol. Pharmacol. 60, 1260-1267 (2001).
17. Kirchheiner, J. et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9, 1-32 (2004).
18. Gaedigk, A., Ryder, D.L., Bradford, L.D. & Leeder, J.S. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay testing for the 1584G promoter polymorphism. Clin. Chem. 49, 1008-1011 (2003).
19. Bertilsson, L. et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther. 51, 388-397 (1992).
20. Funck-Brentano, C., Boëlle, P.Y., Verstuyft, C., Bornert, C., Becquemont, L. & Poirier, J.M. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur. J. Clin. Pharmacol. 61, 821-829 (2005).
21. Spina, E. & de Leon, J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin. Pharmacol. Toxicol. 100, 4-22 (2007).
22. Gaedigk, A., Gotschall, R.R., Forbes, N.S., Simon, S.D. & Leeder, J.S. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 9, 669-682 (1999).
23. Kennedy, M.-J. et al. Chronic intermittent nocturnal hypoxemia alters activities of hepatic cytochrome P4501A2 (CYP1A2), N-acetyltransferase 2 (NAT2), and xanthine oxidase (XO) in children with obstructive sleep apnea (OSA). Clin. Pharmacol. Ther. 79, 33 (2006).
24. Kennedy, M.J., Scripture, C.D., Kashuba, A.D.M., Scott, C.S., Gaedigk, A. & Kearns, G.L. Activities of cytochrome P450 1A, N-acetyltransferase 2, xanthine oxidase and cytochrome P450 2D6 are unaltered in children with cystic fibrosis. Clin. Pharmacol. Ther. 75, 163-171 (2004).
25. Kennedy, M.J. et al. Recombinant human growth hormone (rhGH) has no effect on activities of hepatic cytochrome P450 1A2 (CYP1A2), N-acetyltransferase 2 (NAT2), xanthine oxidase (XO) or cytochrome P450 2D6 (CYP2D6) in children with idiopathic growth hormone deficiency. Clin. Pharmacol. Ther. 79, 84 (2006).
26. Gaedigk, A., Alander, S.W., Bradford, L.D. & Leeder, J.S. CYP2D6*36 gene arrangements within the CYP2D6 locus: Association of CYP2D6*36 with poor metabolizer status. Drug Metab. Dispos. 34, 563-569 (2006).
27. Gaedigk, A. et al. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin. Pharmacol. Ther. 81, 242-251 (2007).
28. Gaedigk, A. et al. Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotype. Clin. Pharmacol. Ther. 81, 517-520 (2007).
29. Gaedigk, A., Ndjountsché, L., Gaedigk, R., Bradford, L.D. & Leeder, J.S. Discovery of a novel non-functional cytochrome P4502D6 allele, CYP2D6*42, in African Americans. Clin. Pharmacol. Ther. 73, 575-576 (2003).
30. Steen, V.M. et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 5, 215-223 (1995).
31. Abdel-Rahman, S.M., Gotschall, R.R., Kauffman, R.E., Leeder, J.S. & Kearns, G.L. Investigation of terbinafine as a CYP2D6 inhibitor in vivo. Clin. Pharmacol. Ther. 65, 465-472 (1999).
32. Schmid, B., Bircher, J., Preisig, R. & Küpfer, A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative-demethylation with debrisoquine hydroxylation. Clin. Pharmacol. Ther. 38, 618-624 (1985).